ArticleHaematologica2026
Sequential therapy with allogeneic HCT in patients aged ≥70 years with active AML: a single-center retrospective analysis.
Article in Haematologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients ≥70 years with relapsed/refractory acute myeloid leukemia (AML) have an extremely poor prognosis. We adopted a sequential therapy approach, aiming to proceed directly to allogeneic hematopoietic cell transplantation (HCT) despite active disease. We analyzed results of all consecutive patients aged over 70 years and diagnosed with primary refractory/ relapsed AML who underwent HCT with sequential therapy approach (FITCy regimen) in the Tel Aviv Sourasky Medical Center. Fifty-one patients (median age 72 years; primary refractory N=42; relapse N=9). Median follow-up was 35 (range, 12-91) months. Incidences of overall and grade 3-4 acute graft-versus-host disease (GVHD) were 39.2% (95% confidence interval [CI]: 25.6-52.8), and 5.9% (95% CI: 0.0-12.5), respectively. Incidences of overall and moderate-severe chronic GVHD were 40.0% (95% CI: 25.7-57.1) and 29.4% (95% CI: 13.2-46.9), respectively. Non-relapse mortality at 3 years was 36% (95% CI: 22- 49). Forty-two of 51 patients (82.4%) had CR on day +30 post HCT. Relapse incidence at 3 years was 27.8% (95% CI: 14.3-41.2). GVHD-free relapse-free and overall survival (OS) at 3-years were 30% (95% CI: 19-47) and 31% (95% CI: 17-55), respectively. Multivariable analysis showed that worse European LeukemiaNet 2022 score, relapsed AML (vs. primary-refractory), not receiving ATG, and lower albumin prior to conditioning, were associated with higher mortality. We developed a model to predict OS that showed median OS in the low-, intermediate-, and high-risk group, not reached, 32.9 months, and 2.1 months, respectively, P<0.001. We conclude that sequential therapy in elderly patients with active AML demonstrates a strong anti- leukemic effect, and age alone should not be a barrier to this strategy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.